Skip to Content

Uplizna (inebilizumab) Disease Interactions

There are 4 disease interactions with Uplizna (inebilizumab):

Major

Inebilizumab (Includes Uplizna) ↔ hepatitis B

Major Potential Hazard, Moderate plausibility. Applies to: Infectious Hepatitis

The use of inebilizumab is contraindicated in patients with active hepatitis B infection.

Major

Inebilizumab (Includes Uplizna) ↔ tuberculosis

Major Potential Hazard, Moderate plausibility. Applies to: Tuberculosis -- Active, Tuberculosis -- Latent

The use of inebilizumab is contraindicated in patients with active or untreated latent tuberculosis.

Moderate

Inebilizumab (Includes Uplizna) ↔ infections

Moderate Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

An increased risk of infections has been observed with the use of inebilizumab. It is recommended to delay administration in patients with an active infection until the infection is resolved. Perform HBV screening in all patients before initiation of treatment. Do not administer this agent to patients with active hepatitis. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating treatment. Consider anti-tuberculosis therapy in patients with a history of latent active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating therapy is appropriate before starting treatment.

Moderate

Inebilizumab (Includes Uplizna) ↔ vaccination

Moderate Potential Hazard, Moderate plausibility. Applies to: Vaccination

The use of live attenuated-vaccines or live vaccines is not recommended during treatment with inebilizumab until B-cell repletion. Administer all required immunizations at least 4 weeks prior to initiation of inebilizumab. The safety of immunization with live or live-attenuated vaccines following inebilizumab therapy has not been studied, therefore it is not recommended during treatment until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to inebilizumab during pregnancy before confirming recovery of B-cell counts. Non-live vaccines, may be administered prior to recovery from B-cell and immunoglobulin level depletion, but to assess whether a protective immune response was mounted, consultation with a qualified specialist should be considered.

Uplizna (inebilizumab) drug interactions

There are 102 drug interactions with Uplizna (inebilizumab)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.